Patients receiving onabotulinumtoxinA demonstrated significantly improved quality of life scores at @ and @ days after treatment ( p = @ and @ , respectively ) as well as significantly lower International Consultation on Incontinence Questionnaire ( ICIQ ) scores ( p < @ ) .